Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA4576377002
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BT4589
INM
InMed Pharmaceuticals Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
InMed Pharmaceuticals Inc.
ISIN
CA4576377002
TICKER
INM
MIC
XNAS
REUTERS
INM.OQ
BLOOMBERG
INM US
Fr., 18.09.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listi...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 3...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 22.07.2026       InMed Pharma
CA4576377002

WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued development of Mentari's pipel...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 07.07.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Na...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       InMed Pharma
CA4576377002

In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       InMed Pharma
CA4576377002

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company.Halper Sadeh encourages InMed shareholders to click here to learn more abo...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       InMed Pharma
CA4576377002

Instrument ID [21629377] (MWG - CA4576377002) suspended...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreeme...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 27.04.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreemen...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualification...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       InMed Pharma
CA4576377002

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsVancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       InMed Pharma
CA4576377002

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical compan...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly ow...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second q...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting o...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 18.11.2025       InMed Pharma
CA4576377002

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical co...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first qua...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 16.10.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board o...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 23.09.2025       InMed Pharma
CA4576377002

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathologyFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular DegenerationCash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026Vancouver, British Columbia...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 05.09.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H....
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 28.07.2025       InMed Pharma
CA4576377002

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activityVancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 27.06.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced pri...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 25.06.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreeme...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 24.06.2025       InMed Pharma
CA4576377002

Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. -...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Fr., 13.06.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Marcum LLP has resigned as InMed's aud...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal ye...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 13.02.2025       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fis...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mo., 03.02.2025       InMed Pharma
CA4576377002

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety marginDose ranging studies completed Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - InMed Pharmaceuticals Inc....
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Mi., 22.01.2025       InMed Pharma
CA4576377002

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compoundsPatent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's disease, Alzheimer's disease and dementiaPatent also prote...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 21.01.2025       InMed Pharma
CA4576377002

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed a reduction of several key neuroinflammatory genes in the brainVancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceutic...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholde...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (th...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       InMed Pharma
CA4576377002

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effectsSupports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritusAnti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic applicationVancouver, British Columbia--(Ne...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       InMed Pharma
CA4576377002

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the first quarter of the fisc...
Zur Nachricht
InMed Pharma
Charts & Research Termsheets Terminal
Permalink